Literature DB >> 26542361

Different expression of VEGF and EGFL7 in human hepatocellular carcinoma.

Luisa Campagnolo1, Claudia Telesca2, Micol Massimiani1, Heidi Stuhlmann3, Mario Angelico2, Ilaria Lenci2, Tommaso M Manzia2, Laura Tariciotti2, Giorgia Lehmann1, Leonardo Baiocchi4.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is one of several angiogenic factors expressed in cirrhosis and during progression to malignancy, that seem to play a major role in hepatocellular carcinoma development. Lately, another angiogenic factor, epidermal growth factor-like domain multiple 7 (EGFL7), has attracted interest due to its possible relationship with hepatocellular carcinoma metastasis. AIMS: To evaluate expression of VEGF and EGFL7 in human hepatocellular carcinoma, compared to corresponding cirrhotic surrounding tissue.
METHODS: Tumoural and cirrhotic tissue was harvested from 12 consecutive patients undergoing surgical resection. VEGF and EGFL7 were assessed by immunofluorescence and quantitative reverse transcriptase-polymerase chain reaction, compared with normal controls.
RESULTS: Both angiogenic factors were over-expressed in cirrhotic livers compared to normal controls. VEGF and EGFL7 expressions did not differ according to disease aetiology, nodule size or other clinical variables. While VEGF expression was constant, regardless of tumour differentiation stage and unchanged compared to surrounding cirrhotic tissue, EGFL7 expression increased in less differentiated hepatocellular carcinoma.
CONCLUSIONS: The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase.
Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidermal growth factor like domain 7 (EGFL7); Hepatocellular carcinoma (HCC); Liver cirrhosis; Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2015        PMID: 26542361     DOI: 10.1016/j.dld.2015.09.019

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  8 in total

1.  Differential expression of angiogenesis-related miRNAs and VEGFA in cirrhosis and hepatocellular carcinoma.

Authors:  André R C P de Oliveira; Márcia M U Castanhole-Nunes; Patrícia M Biselli-Chicote; Érika C Pavarino; Rita de C M A da Silva; Renato F da Silva; Eny M Goloni-Bertollo
Journal:  Arch Med Sci       Date:  2020-08-10       Impact factor: 3.318

2.  Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma.

Authors:  Caterina L Mammola; Antonella Vetuschi; Luigi Pannarale; Roberta Sferra; Romina Mancinelli
Journal:  Eur J Histochem       Date:  2018-11-30       Impact factor: 3.188

3.  Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.

Authors:  Guolin Huang; Li Li; Chaoyong Liang; Fei Yu; Cuifang Teng; Yingxing Pang; Tongtong Wei; Jinjing Song; Hanlin Wang; Xiaoli Liao; Yongqiang Li; Jie Yang
Journal:  Pharmacol Res Perspect       Date:  2021-02

4.  Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma.

Authors:  Barbara Vizio; Ornella Bosco; Ezio David; Gian Paolo Caviglia; Maria Lorena Abate; Martina Schiavello; Angela Pucci; Antonina Smedile; Gianluca Paraluppi; Renato Romagnoli; Enrico Lupia; Graziella Bellone; Giuseppe Montrucchio
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

5.  The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility.

Authors:  Weipeng Liu; Yunyun Zhang; Fengdan Huang; Qianli Ma; Chuanyin Li; Shuyuan Liu; Yan Liang; Li Shi; Yufeng Yao
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

6.  Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma.

Authors:  Cheng Gong; Jing Fang; Guang Li; Han-Han Liu; Zhi-Su Liu
Journal:  Oncotarget       Date:  2017-04-20

7.  Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy.

Authors:  Guang-Zhi Zhu; Xi-Wen Liao; Xiang-Kun Wang; Yi-Zhen Gong; Xiao-Guang Liu; Long Yu; Chuang-Ye Han; Cheng-Kun Yang; Hao Su; Ke-Tuan Huang; Ting-Dong Yu; Jian-Lu Huang; Jia Li; Zhi-Ming Zeng; Wei Qin; Zheng-Qian Liu; Xin Zhou; Jun-Qi Liu; Lei Lu; Quan-Fa Han; Li-Ming Shang; Xin-Ping Ye; Tao Peng
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

8.  Spatial maps of hepatocellular carcinoma transcriptomes highlight an unexplored landscape of heterogeneity and a novel gene signature for survival.

Authors:  Nan Zhao; Yanhui Zhang; Runfen Cheng; Danfang Zhang; Fan Li; Yuhong Guo; Zhiqiang Qiu; Xueyi Dong; Xinchao Ban; Baocun Sun; Xiulan Zhao
Journal:  Cancer Cell Int       Date:  2022-02-02       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.